Prognostic Factors Identifiable at the Time of Onset of Acute Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation
Overview
Authors
Affiliations
Background And Objectives: Current grading systems of acute graft-versus-host disease (GVHD) cannot effectively identify patients with poor prognosis at the onset of acute GVHD after allogeneic hematopoietic cell transplantation.
Design And Methods: In a retrospective analysis, we evaluated the prognostic value of various clinical parameters at the initiation of treatment in 83 patients who developed systemic treatment-requiring acute GVHD after allogeneic hematopoietic cell transplantation.
Results: Forty-three of 83 patients (52%) experienced initial treatment failure (40 required secondary treatment due to lack of response and 3 died) and 43 (52%) experienced treatment success, defined as completion of treatment (initial and, if given, secondary) within 100 days. The GVHD-specific survival rate was 65.5%, with 27 deaths due to GVHD-related complications without relapse of underlying malignancies within 1 year. HLA-mismatched transplantation, visceral initiation, and peripheral blood lymphocytopenia ( pound100/mL) were independent variables predicting higher initial treatment failure (Odd ratios (OR)=12.225, 12.036, and 7.481, respectively). The above variables and initial acute GVHD grade III-IV vs. II were independent variables predicting shorter GVHD-specific survival (OR=0.322, 0.247, 0.340, and 0.385, respectively). High-risk disease status, visceral initiation, and hypoalbuminemia ( pound2.8 g/dL) were independent variables predicting lower treatment success (OR=0.221, 0.162, and 0.270, respectively). The predictive value of visceral initiation and lymphocytopenia for GVHD-specific survival was verified in an independent cohort of 58 patients.
Interpretation And Conclusions: Lymphocytopenia and hypoalbuminemia may be useful baseline prognostic factors for acute GVHD after allogeneic hematopoietic cell transplantation.
α-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease.
Magenau J, Goldstein S, Peltier D, Soiffer R, Braun T, Pawarode A Blood. 2018; 131(12):1372-1379.
PMID: 29437593 PMC: 5865235. DOI: 10.1182/blood-2017-11-815746.
Dai Z, Liu J, Zhang W, Cao X, Zhang Y, Dai Z Mol Clin Oncol. 2016; 4(4):667-671.
PMID: 27073687 PMC: 4812520. DOI: 10.3892/mco.2016.765.
A risk-adapted approach to acute GVHD treatment: are we there yet?.
Holtan S, MacMillan M Bone Marrow Transplant. 2015; 51(2):172-5.
PMID: 26551780 DOI: 10.1038/bmt.2015.261.
Bayraktar U, Milton D, Guindani M, Rondon G, Chen J, Al-Atrash G Biol Blood Marrow Transplant. 2015; 22(3):505-13.
PMID: 26524730 PMC: 7107718. DOI: 10.1016/j.bbmt.2015.10.020.
Alam N, Xu W, Atenafu E, Uhm J, Seftel M, Gupta V Bone Marrow Transplant. 2015; 50(5):734-42.
PMID: 25774595 DOI: 10.1038/bmt.2015.19.